SCHEMBL1158751

SCHEMBL1158751

CCN1CCC[C@H]1CNc1nc(Nc2cc(C)ccn2)cc2cc[nH]c(=O)c12

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FER P16591 1/20 0.41
SYK P43405 1/20 0.39
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 4/20 0.38
HSD17B10 Q99714 3/20 0.38
HPGD P15428 3/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
DRD2 P14416 1/20 0.38
IRAK4 Q9NWZ3 2/20 0.38
MAP3K12 Q12852 7/20 0.37
ACHE P22303 1/20 0.36
ZAP70 P43403 1/20 0.36
CYP3A4 P08684 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
KMT2A Q03164 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158012 1.00 FER (0.41) FERSYKKDM4EALDH1A1HSD17B10
SCHEMBL1158163 0.84 FER (0.44) FERSYKMAP3K12ZAP70
SCHEMBL1159458 0.83 SYK (0.41) FERSYKMAP3K12ZAP70
SCHEMBL1158652 0.81 FER (0.41) FERSYKALDH1A1ZAP70KMT2A
SCHEMBL1158435 0.81 BRD4 (0.52) FERSYKMAP3K12ZAP70
SCHEMBL1158658 0.80 FER (0.42) FERSYKKDM4EALDH1A1HSD17B10
SCHEMBL1158282 0.80 FER (0.42) FERSYKKDM4EALDH1A1HSD17B10
SCHEMBL12848848 0.79 FER (0.40) FERSYKKDM4EHPGDZAP70
SCHEMBL1158890 0.78 SYK (0.54) FERSYKKDM4EALDH1A1MAP3K12
SCHEMBL1158606 0.78 SYK (0.54) FERSYKKDM4EALDH1A1MAP3K12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN FER 89/4885SYK 1/4885KDM4E 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.